Hollings enrolled the first patient in a clinical trial of a new type of drug, a bifunctional antibody, for head and neck squamous cell carcinoma.

Ask researchers what the toughest part of their work is, and many will tell you it isn’t complex experiments – it's translating science into a story.

15 years after a terminal diagnosis, Nathan Calhoun is alive thanks to a clinical trial. It's why he performed at LOWVELO in 2024.

Gene therapy is being used against diseases like sickle cell and hemophilia. Could it be used against cancer?

The cochlear implant team at MUSC Health adds a new clinical trial that’s testing a device that may reduce hearing loss that can happen as an implant goes in.

Hollings researchers want to help older adults with head and neck cancer navigate treatment options that have mostly been studied among middle-aged adults.

MUSC Hollings Cancer Center researchers will test whether e-cigarettes are a viable quit smoking option for people who decline other options.

“There's an incredible amount of excitement about this device.” MUSC prepares to place totally under-the-skin cochlear implants in patients with hearing loss.

The U.S. surgeon general is calling attention to the link between alcohol and cancer, a connection that may be news to the general public.

Hollings researcher receives Department of Defense Early Career Scholar Award to improve immune therapies by targeting resistant kidney tumors.